|
« Duetact Bladder Cancer Side Effect |
Main
| California Actos Bladder Cancer Lawsuit »
|
 |
|
Actoplus Met Bladder Cancer Risk
|
The FDA has warned that long-term use of the diabetes drug Actoplus Met and its extended release form, Actoplus Met XR, comes with an increased risk of bladder cancer. Although most of the coverage in the news and on the internet has focused on Actos, the FDA has also warned that the use of Actoplus Met and Actoplus Met XR increases the risk of bladder cancer.
Actoplus Met and Actoplus Met XR are the brand names for tablets that combine Actos (pioglitazone) with the more common diabetes drug, metformin hydrocholride. Actoplus Met was approved for sale in the United States in 2005. Actoplus Met XR was approved in 2009. Like
Actos, Actoplus Met and Actoplus Met XR are manufactured by a Japanese pharmaceutical company, Takeda Pharmaceuticals. Also like
Actos, studies have shown that long-term use of Actoplus Met and its extended release form increase the risk of developing bladder cancer.
If you or a loved one developed bladder cancer after using Actoplus Met or Actoplus Met XR for more than one year, there is a possibility the cancer was caused by Actoplus Met or Actoplus Met XR. Because Takeda Pharmaceuticals did not warn that using these drugs might cause bladder cancer, Takeda Pharmaceuticals may be legally liable for the injury.
Learn more about the risks of Actoplus Met and Actoplus Met XR HERE.
|
|
|
|
|
|
|
Posted By DeCarli Law on
August 19, 2011 05:40 am |
Permalink
|
|